The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Abstract
The preclinical pharmacology of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation agent is described. Varenicline binds with subnanomolar affinity only to alpha4beta2 nAChRs and in vitro functional patch clamp studies in HEK cells expressing nAChRs show that varenicline is a partial agonist with 45% of nicotine's maximal efficacy at alpha4beta2 nAChRs. In neurochemical models varenicline has significantly lower (40-60%) efficacy than nicotine in stimulating [(3)H]-dopamine release from rat brain slices in vitro and in increasing dopamine release from rat nucleus accumbens in vivo, while it is more potent than nicotine. In addition, when combined with nicotine, varenicline effectively attenuates the nicotine-induced dopamine release to the level of the effect of varenicline alone, consistent with partial agonism. Finally, varenicline reduces nicotine self-administration in rats and supports lower self-administration break points than nicotine. These data suggest that varenicline can reproduce to some extent the subjective effects of smoking by partially activating alpha4beta2 nAChRs, while preventing full activation of these receptors by nicotine. Based on these findings, varenicline was advanced into clinical development and recently shown to be an effective and safe aid for smoking cessation treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither patch (Jorenby et al., 1995) nor varenicline are reinforcing (Rollema et al., 2007).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although the K i values for sazetidine-A and varenicline at ␣42 nAChRs are very similar (0.4 and 0.2 nM, respectively) (Xiao et al., 2006;Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although varenicline, like cytisine, is a potent and selective ␣42 partial agonist (Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“The fact that low doses of varenicline (i.e. 0.25 mg/kg in C57BL/6J mice and 0.178 mg/kg in CD-1 mice) have significant effects in both experiments is consistent with varenicline’s high in vitro binding affinity (Ki = 0.15 nM) and inactivating potency (IC50 = 6 nM) at α4β2 nicotinic acetylcholine receptors, as well as with its potent activity in in vivo models, such as increasing mesolimbic”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“Department of Health and Human Services, 2004; Doll et al., 2004 ).”
BackgroundThe Health Consequences of Smoking: A Report of the Surgeon General
Office on Smoking (2004) · Cited by 2,414
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citation
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–554 of 554
Ng, G. (2015) · TSpace (University of Toronto)
Staios, G. (2011) · TSpace (University of Toronto)
The Effects of Binge-Like Sucrose Consumption on the Mesolimbic Reward Pathway in the Brain
Shariff, M. R. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.107900
Guy, E. G. (2014) · TSpace (University of Toronto)
Modeling ion permeation in wild-type and mutant human α7 nachr ion channels
Kucukkal, T. G., Alsaiari, F., & Stuart, S. J. (2018) · Journal of Theoretical and Computational Chemistry · doi:10.1142/s0219633618500451
Holgate, J. Y. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.121485
DIABETE, TABAGISMO E DISASSUEFAZIONE DAL FUMO
Campagna, D., Alamo, A., Mondati, E. G. M., & Polosa, R. (2019) · il Diabete · doi:10.30682/ildia1901d
Varenicline: Treating Smoking Addiction and Schizophrenia
Jung, D.-U., & Kim, S.-J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813035-3.00056-3
Maggio, S. E. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.395
Agents for Treatment of Withdrawal and Dependency: Varenicline
Jacob, C. C., & Polak, T. T. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_350-1
Dastgerdi, G. (2020) · Scholarly Journal of Psychology and Behavioral Sciences · doi:10.32474/sjpbs.2020.03.000171
Factors Influencing the Effectiveness of Mass Distribution of Free Nicotine Replacement Therapy
KUSHNIR, V. N. (2018) · TSpace (University of Toronto)
Townsend, C. Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00003-7
Garcia‐Rivas, V., Fiancette, J.-F., Tostain, J., de Maio, G., Wiart, J., Gaulier, J., & Deroche‐Gamonet, V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.05.463198
Preventing and Treating Tobacco Use
Ferschke, N. (2021) · Physician Assistant Clinics · doi:10.1016/j.cpha.2021.08.007
LaMattina, J. L. (2008) · Wiley eBooks · doi:10.1002/9780470434673.refs
Psychopharmakotherapie: pharmakologische Grundlagen
Müller, W. E. G., & Eckert, A. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_27
Buckley, P. F. (2008) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.2.1.1
The Pharmacist's Role in Smoking Cessation
Wick, J. Y. (2008) · The Consultant Pharmacist · doi:10.4140/tcp.n.2008.68
Yunusoğlu, O., KÖSE, Ç., Shahzadi, A., Demir, B., Önal, B., Özyazgan, S., & Akkan, A. G. (2022) · Archives of Current Medical Research · doi:10.47482/acmr.1159319
Agents for Treatment of Withdrawal and Dependency: Varenicline
Jacob, C. C., & Polak, T. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_350
Bernat, P., Kołodziejczyk, P., Łuszczki, J. J., Zagaja, M. P., & Tutka, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032616
Modulators of nicotine reward and reinforcement
Henderson, B. J., Tetteh-Quarshie, S., & Olszewski, N. A. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2023.10.005
Qing, G., Taorigen, H., Zhou, Y., & Wang, G. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02799-w
Neurotransmitters and Neural Pathways
Schnall, J. S. (2026) · Springer eBooks · doi:10.1007/978-3-031-57159-6_33-1
Gofarana, W. (2020) · Institutional Repositories DataBase (IRDB)
Tiwari, R. K., Sharma, B., Sharma, A. K., & Pandey, R. (2026) · Current Neurovascular Research · doi:10.2174/0115672026440701260331063904
Discriminative stimulus and locomotor activity profiles of nicotine and varenicline
Kusi-Boadum, N. K., Taylor, C. M., Shetty, R. A., Sumien, N., & Forster, M. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174213
Mutukula, S., Gagne-Hatfield, T., & Dunbar, Z. R. (2026) · Medicines · doi:10.3390/medicines13020019
Challenges in Anti-addiction Drug Development: Lost in Translation?
Li, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0011
Cronin, E. A., Galbo, L. K., Epperly, P. M., Blough, B. E., Landavazo, A., Gould, R. W., & Czoty, P. W. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179199
Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation
Hefny, A. A., Karuturi, R. C., Kalyaanamoorthy, S., Rao, P. P. N., & Ganesan, A. (2026) · Biology · doi:10.3390/biology15161412
Bagul, V. A., & Ambadekar, S. R. (2026) · Discover Industrial Chemistry and Materials · doi:10.1007/s44508-026-00019-6
Comparison of first-line smoking cessation medications and the theory of new smoking cessation drugs
Xie, X. (2026) · Journal of Food Science Nutrition and Health · doi:10.54254/3029-0821/2026.37541
BindingDB (2021) · UC San Diego · doi:10.7270/q29027bj
BindingDB (2014) · UC San Diego · doi:10.7270/q2jw8gbv
Regulation of Neuronal Nicotinic Receptor Expression by Novel Ligands and Mechanisms
Hussmann, G. P. (2012) · DigitalGeorgetown (Georgetown University Library)
Metadata
- Authors
- Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., & Williams, K. E.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Rollema, H.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 52
- Issue
- 3
- Pages
- 985-994
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2101520329
- Cited by
- 533
- References
- 44
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 19 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 20 · 2016: 27 · 2015: 37 · 2014: 34 · 2013: 34 · 2012: 41
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- varenicline, α4β2 nicotinic acetylcholine receptor, partial agonism, smoking cessation, nicotine self-administration, dopamine release, nucleus accumbens, receptor binding affinity
- MeSH terms
- Varenicline, Animals, Behavior, Animal, Benzazepines, Brain, Cell Line, Transformed, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Membrane Potentials, Nicotine, Protein Binding, Quinoxalines, Self Administration, Transfection, Smoking Cessation, Rats, Sprague-Dawley, Patch-Clamp Techniques, Nicotinic Agonists, Rats, Long-Evans, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
